FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313855225> ?p ?o ?g. }

• W4313855225 endingPage "730" @default.
• W4313855225 startingPage "717" @default.
• W4313855225 abstract "We recently developed a heterologous therapeutic vaccination scheme (TherVacB) comprising a particulate protein prime followed by a modified vaccinia-virus Ankara (MVA)-vector boost for the treatment of HBV. However, the key determinants required to overcome HBV-specific immune tolerance remain unclear. Herein, we aimed to study new combination adjuvants and unravel factors that are essential for the antiviral efficacy of TherVacB.Recombinant hepatitis B surface and core antigen (HBsAg and HBcAg) particles were formulated with different liposome- or oil-in-water emulsion-based combination adjuvants containing saponin QS21 and monophosphoryl lipid A; these formulations were compared to STING-agonist c-di-AMP and conventional aluminium hydroxide formulations. Immunogenicity and the antiviral effects of protein antigen formulations and the MVA-vector boost within TherVacB were evaluated in adeno-associated virus-HBV-infected and HBV-transgenic mice.Combination adjuvant formulations preserved HBsAg and HBcAg integrity for ≥12 weeks, promoted human and mouse dendritic cell activation and, within TherVacB, elicited robust HBV-specific antibody and T-cell responses in wild-type and HBV-carrier mice. Combination adjuvants that prime a balanced HBV-specific type 1 and 2 T helper response induced high-titer anti-HBs antibodies, cytotoxic T-cell responses and long-term control of HBV. In the absence of an MVA-vector boost or following selective CD8 T-cell depletion, HBsAg still declined (mediated mainly by anti-HBs antibodies) but HBV replication was not controlled. Selective CD4 T-cell depletion during the priming phase of TherVacB resulted in a complete loss of vaccine-induced immune responses and its therapeutic antiviral effect in mice.Our results identify CD4 T-cell activation during the priming phase of TherVacB as a key determinant of HBV-specific antibody and CD8 T-cell responses.Therapeutic vaccination is a potentially curative treatment option for chronic hepatitis B. However, it remains unclear which factors are essential for breaking immune tolerance in HBV carriers and determining successful outcomes. Our study provides the first direct evidence that efficient priming of HBV-specific CD4 T cells determines the success of therapeutic hepatitis B vaccination in two preclinical HBV-carrier mouse models. Applying an optimal formulation of HBV antigens that activates CD4 and CD8 T cells during prime immunization provided the foundation for an antiviral effect of therapeutic vaccination, while depletion of CD4 T cells led to a complete loss of vaccine-induced antiviral efficacy. Boosting CD8 T cells was important to finally control HBV in these mouse models. Our findings provide important insights into the rational design of therapeutic vaccines for the cure of chronic hepatitis B." @default.
• W4313855225 created "2023-01-10" @default.
• W4313855225 creator A5003012054 @default.
• W4313855225 creator A5013132368 @default.
• W4313855225 creator A5013201313 @default.
• W4313855225 creator A5032861890 @default.
• W4313855225 creator A5034740021 @default.
• W4313855225 creator A5048210728 @default.
• W4313855225 creator A5049604548 @default.
• W4313855225 creator A5054907440 @default.
• W4313855225 creator A5067065960 @default.
• W4313855225 creator A5070461413 @default.
• W4313855225 creator A5072749856 @default.
• W4313855225 creator A5073189385 @default.
• W4313855225 creator A5089690524 @default.
• W4313855225 creator A5091595561 @default.
• W4313855225 date "2023-04-01" @default.
• W4313855225 modified "2023-10-01" @default.
• W4313855225 title "Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models" @default.
• W4313855225 cites W1968529896 @default.
• W4313855225 cites W1969776963 @default.
• W4313855225 cites W2011555137 @default.
• W4313855225 cites W2077359319 @default.
• W4313855225 cites W2087932916 @default.
• W4313855225 cites W2098459535 @default.
• W4313855225 cites W2101273158 @default.
• W4313855225 cites W2129651659 @default.
• W4313855225 cites W2130834121 @default.
• W4313855225 cites W2138674743 @default.
• W4313855225 cites W2144887013 @default.
• W4313855225 cites W2146785346 @default.
• W4313855225 cites W2149042360 @default.
• W4313855225 cites W2234448540 @default.
• W4313855225 cites W2519431323 @default.
• W4313855225 cites W2535094711 @default.
• W4313855225 cites W2609065752 @default.
• W4313855225 cites W2739683242 @default.
• W4313855225 cites W2792649187 @default.
• W4313855225 cites W2794867040 @default.
• W4313855225 cites W2886930165 @default.
• W4313855225 cites W2898262045 @default.
• W4313855225 cites W2913058760 @default.
• W4313855225 cites W2963151297 @default.
• W4313855225 cites W2997709843 @default.
• W4313855225 cites W3003378907 @default.
• W4313855225 cites W3144140615 @default.
• W4313855225 doi "https://doi.org/10.1016/j.jhep.2022.12.013" @default.
• W4313855225 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36634821" @default.
• W4313855225 hasPublicationYear "2023" @default.
• W4313855225 type Work @default.
• W4313855225 citedByCount "3" @default.
• W4313855225 countsByYear W43138552252023 @default.
• W4313855225 crossrefType "journal-article" @default.
• W4313855225 hasAuthorship W4313855225A5003012054 @default.
• W4313855225 hasAuthorship W4313855225A5013132368 @default.
• W4313855225 hasAuthorship W4313855225A5013201313 @default.
• W4313855225 hasAuthorship W4313855225A5032861890 @default.
• W4313855225 hasAuthorship W4313855225A5034740021 @default.
• W4313855225 hasAuthorship W4313855225A5048210728 @default.
• W4313855225 hasAuthorship W4313855225A5049604548 @default.
• W4313855225 hasAuthorship W4313855225A5054907440 @default.
• W4313855225 hasAuthorship W4313855225A5067065960 @default.
• W4313855225 hasAuthorship W4313855225A5070461413 @default.
• W4313855225 hasAuthorship W4313855225A5072749856 @default.
• W4313855225 hasAuthorship W4313855225A5073189385 @default.
• W4313855225 hasAuthorship W4313855225A5089690524 @default.
• W4313855225 hasAuthorship W4313855225A5091595561 @default.
• W4313855225 hasBestOaLocation W43138552251 @default.
• W4313855225 hasConcept C104317684 @default.
• W4313855225 hasConcept C147483822 @default.
• W4313855225 hasConcept C154317977 @default.
• W4313855225 hasConcept C159047783 @default.
• W4313855225 hasConcept C202751555 @default.
• W4313855225 hasConcept C203014093 @default.
• W4313855225 hasConcept C2522874641 @default.
• W4313855225 hasConcept C2776090121 @default.
• W4313855225 hasConcept C2777410769 @default.
• W4313855225 hasConcept C2777863537 @default.
• W4313855225 hasConcept C2779729466 @default.
• W4313855225 hasConcept C2780593183 @default.
• W4313855225 hasConcept C2780868878 @default.
• W4313855225 hasConcept C32470452 @default.
• W4313855225 hasConcept C40767141 @default.
• W4313855225 hasConcept C55493867 @default.
• W4313855225 hasConcept C71924100 @default.
• W4313855225 hasConcept C86803240 @default.
• W4313855225 hasConcept C8891405 @default.
• W4313855225 hasConceptScore W4313855225C104317684 @default.
• W4313855225 hasConceptScore W4313855225C147483822 @default.
• W4313855225 hasConceptScore W4313855225C154317977 @default.
• W4313855225 hasConceptScore W4313855225C159047783 @default.
• W4313855225 hasConceptScore W4313855225C202751555 @default.
• W4313855225 hasConceptScore W4313855225C203014093 @default.
• W4313855225 hasConceptScore W4313855225C2522874641 @default.
• W4313855225 hasConceptScore W4313855225C2776090121 @default.
• W4313855225 hasConceptScore W4313855225C2777410769 @default.
• W4313855225 hasConceptScore W4313855225C2777863537 @default.
• W4313855225 hasConceptScore W4313855225C2779729466 @default.

• next